Publications by authors named "G. Wlodarczak"
Article Synopsis
- The BIOMAG-I study evaluated the first-in-human resorbable magnesium scaffold (DREAMS 3G) and showed positive outcomes for clinical results and late lumen loss after 12 months.
- The current substudy looked into vascular healing parameters using optical coherence tomography (OCT) and intravascular ultrasound (IVUS), focusing on aspects like strut visibility and neointimal growth.
- Results from 56 patients indicated that almost all scaffold struts became invisible by 12 months, with a favorable vascular healing response, including a significant decrease in protruding neointimal tissue.
Temporal changes in coronary plaque as assessed by an artificial intelligence-based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold.
Eur Heart J Cardiovasc Imaging
March 2024
Article Synopsis
- The study aimed to evaluate how the initial composition of plaque affects late loss in the lumen after DREAMS 3G implantation and to compare plaque changes over 6 and 12 months.
- 116 patients from the BIOMAG-I trial underwent imaging using optical coherence tomography (OCT) before and after the procedure, revealing that those with more fibrous tissue in their plaque initially had greater differences in lumen area after a year.
- Results showed a significant reduction in lipid areas and an increase in fibrous tissue at follow-up, indicating favorable healing of coronary walls post-implantation.
Fractional calculus is an essential tool in studying new phenomena in hydromechanics and heat and mass transfer, particularly anomalous hydromechanical advection-dispersion considering the fractal nature of the porous medium. They are valuable in solving the urgent problem of convective mass transfer in a porous medium (e.g.
View Article and Find Full Text PDFArticle Synopsis
- The study compared the safety and effectiveness of two types of stents—biodegradable-polymer sirolimus-eluting stents and durable-polymer zotarolimus-eluting stents—in patients at high bleeding risk receiving abbreviated dual antiplatelet therapy after coronary interventions.
- Conducted as a randomized trial across 52 hospitals in 18 countries, it involved 1,948 patients who were randomized to receive one of the two stent types after successful lesion preparation, followed by 1 month of dual antiplatelet therapy.
- Results showed that at 1 year, the rates of adverse outcomes (death, heart attack, or stent thrombosis) were similar between the two stent types, with
Article Synopsis
- The DREAMS 3G is a new coronary magnesium scaffold designed to match the performance of traditional drug-eluting stents (DES).
- The BIOMAG-I study is a first-in-human trial that evaluates the safety and effectiveness of this scaffold with a follow-up period of up to 5 years.
- Results showed that after 12 months, the scaffold demonstrated low rates of complications, confirming its safety and efficacy as a potential alternative to DES.
Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy.
J Cardiovasc Transl Res
October 2023
Article Synopsis
- The BIOFLOW-DAPT trial investigates the safety of the Orsiro Mission stent versus the Resolute Onyx stent in high bleeding risk patients undergoing PCI, focusing on a 1-month dual antiplatelet therapy (DAPT) regimen.
- The study will assess the occurrence of cardiac death, myocardial infarction, and stent thrombosis over a year, with a total of 1948 participants to ensure reliable results.
- This is the first randomized trial to evaluate a reduced DAPT duration specifically for HBR patients receiving the Orsiro Mission stent, aiming to balance safety and bleeding risk.
Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
EuroIntervention
April 2022
Background: Improvements in drug-eluting stent design have led to a reduced frequency of repeat revascularisation and new biodegradable polymer coatings may allow a shorter duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).
Aims: The Improved Drug-Eluting stent for All-comers Left Main (IDEAL-LM) study aims to investigate long-term clinical outcomes after implantation of a biodegradable polymer platinum-chromium everolimus-eluting stent (BP-PtCr-EES) followed by 4 months DAPT compared to a durable polymer cobalt-chromium everolimus-eluting stent (DP-CoCr-EES) followed by 12 months DAPT in patients undergoing PCI of unprotected left main coronary artery (LMCA) disease.
Methods: This is a multicentre randomised clinical trial study in patients with an indication for coronary artery revascularisation who have been accepted for PCI for LMCA disease after Heart Team consultation.
Background: Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited.
Methods: In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk.
Background: In patients with ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (PCI) to restore blood flow in an infarct-related coronary artery improves outcomes. The use of PCI in non-infarct-related coronary arteries remains controversial.
Methods: We randomly assigned 885 patients with STEMI and multivessel disease who had undergone primary PCI of an infarct-related coronary artery in a 1:2 ratio to undergo complete revascularization of non-infarct-related coronary arteries guided by fractional flow reserve (FFR) (295 patients) or to undergo no revascularization of non-infarct-related coronary arteries (590 patients).